BR112022025626A2 - Uso de vesículas derivadas de lactobacillus paracasei - Google Patents

Uso de vesículas derivadas de lactobacillus paracasei

Info

Publication number
BR112022025626A2
BR112022025626A2 BR112022025626A BR112022025626A BR112022025626A2 BR 112022025626 A2 BR112022025626 A2 BR 112022025626A2 BR 112022025626 A BR112022025626 A BR 112022025626A BR 112022025626 A BR112022025626 A BR 112022025626A BR 112022025626 A2 BR112022025626 A2 BR 112022025626A2
Authority
BR
Brazil
Prior art keywords
lactobacillus paracasei
vesicles derived
mental
disorder
neurological disorder
Prior art date
Application number
BR112022025626A
Other languages
English (en)
Inventor
Kim Yoon-Keun
Original Assignee
Md Healthcare Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020200169167A external-priority patent/KR102257130B1/ko
Application filed by Md Healthcare Inc filed Critical Md Healthcare Inc
Publication of BR112022025626A2 publication Critical patent/BR112022025626A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/316—Foods, ingredients or supplements having a functional effect on health having an effect on regeneration or building of ligaments or muscles
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/3262—Foods, ingredients or supplements having a functional effect on health having an effect on blood cholesterol
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/332—Promoters of weight control and weight loss

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

USO DE VESÍCULAS DERIVADAS DE LACTOBACILLUS PARACASEI. A presente invenção se refere a uma composição para prevenir, melhorar ou tratar um distúrbio neurológico ou um distúrbio mental, compreendendo vesículas derivadas de Lactobacillus paracasei como um ingrediente ativo. Os presentes inventores confirmaram que quando vesículas derivadas de Lactobacillus paracasei foram administradas a um modelo animal transgênico de distúrbio neurológico, as anormalidades na função do nervo cerebral são efetivamente suprimidas, e também confirmaram que quando vesículas derivadas de Lactobacillus paracasei foram administradas a um modelo animal de transtorno mental devido a estresse mental, as anormalidades na função mental devido ao estresse e os distúrbios comportamentais que as acompanham foram efetivamente suprimidos, de modo que as vesículas derivadas de Lactobacillus paracasei de acordo com a presente invenção podem ser usadas de maneira útil para o desenvolvimento de um alimento funcional farmacêutico ou para a saúde, para prevenir um distúrbio neurológico ou um distúrbio mental, melhorar seus sintomas, ou tratar o distúrbio neurológico ou o distúrbio mental, e similares.
BR112022025626A 2020-06-16 2021-03-12 Uso de vesículas derivadas de lactobacillus paracasei BR112022025626A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20200072685 2020-06-16
KR1020200169167A KR102257130B1 (ko) 2020-06-16 2020-12-07 락토바실러스 파라카세이 유래 소포를 포함하는 신경질환 또는 정신질환 예방 또는 치료용 조성물
PCT/KR2021/003075 WO2021256665A1 (ko) 2020-06-16 2021-03-12 락토바실러스 파라카세이 유래 소포를 포함하는 신경질환 또는 정신질환 예방 또는 치료용 조성물

Publications (1)

Publication Number Publication Date
BR112022025626A2 true BR112022025626A2 (pt) 2023-01-17

Family

ID=78824279

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022025626A BR112022025626A2 (pt) 2020-06-16 2021-03-12 Uso de vesículas derivadas de lactobacillus paracasei

Country Status (8)

Country Link
US (2) US11672838B2 (pt)
EP (1) EP3957316B1 (pt)
JP (2) JP7385301B2 (pt)
CN (1) CN114144239B (pt)
AU (1) AU2021291569A1 (pt)
BR (1) BR112022025626A2 (pt)
CA (1) CA3181432A1 (pt)
MX (1) MX2022015535A (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021291569A1 (en) * 2020-06-16 2022-10-20 Md Healthcare Inc. Composition for prevention or treatment of neurological or mental disorders comprising extracellular vesicles derived from lactobacillus paracasei
CN113322213B (zh) * 2021-07-09 2022-05-13 吉林大学 一种具有改善记忆障碍功能的副干酪乳杆菌Jlus66菌剂和应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011027956A2 (ko) * 2009-09-04 2011-03-10 주식회사이언메딕스 그람 양성 박테리아에서 유래한 세포밖 소포체 및 이를 이용한 질병 모델
US20130243728A9 (en) * 2009-11-18 2013-09-19 Agriculture Victoria Services Pty Ltd Recombinant microorganisms
EP2675447A4 (en) * 2011-02-18 2015-04-22 Nestec Sa METHODS AND COMPOSITIONS FOR TREATING, REDUCING OR PREVENTING DAMAGE TO THE NERVOUS ANIMAL SYSTEM
JPWO2015125878A1 (ja) * 2014-02-24 2017-03-30 旭硝子株式会社 熱サイクルシステム用組成物および熱サイクルシステム
US9925225B2 (en) * 2014-09-26 2018-03-27 Nubiome, Inc. Treatment and prophylaxis for gastroesophageal reflux disease
KR20170032815A (ko) * 2015-09-15 2017-03-23 경희대학교 산학협력단 신규 유산균 및 퇴행성 뇌질환 또는 인지기능의 예방, 개선 또는 치료용 조성물
WO2017047962A1 (ko) * 2015-09-15 2017-03-23 경희대학교 산학협력단 신규 유산균 및 퇴행성 뇌질환 또는 인지기능 장애의 예방, 개선 또는 치료용 조성물
WO2017074566A1 (en) * 2015-10-30 2017-05-04 Dean Falb Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
US10363279B2 (en) * 2016-02-20 2019-07-30 Nubiome, Inc. Treatment and prophylaxis for neurological conditions and diseases
KR20180019474A (ko) 2016-08-16 2018-02-26 주식회사 엠디헬스케어 락토바실러스 플란타룸 유래 소포를 포함하는 정신질환 예방 또는 치료용 조성물
KR101853603B1 (ko) * 2017-05-18 2018-05-02 주식회사 쎌바이오텍 알코올 또는 아세트알데하이드 분해용 프로바이오틱스를 포함하는 조성물
MA50086A (fr) * 2017-09-08 2020-07-15 Evelo Biosciences Inc Vésicules extracellulaires (ev) bactériennes
EP3727410B1 (en) * 2017-12-19 2024-06-12 International N&H Denmark ApS Probiotics for cognitive and mental health
WO2019119261A1 (en) * 2017-12-19 2019-06-27 Dupont Nutrition Biosciences Aps Probiotics for cognitive and mental health
WO2019134690A1 (en) * 2018-01-05 2019-07-11 Bened Biomedical Co., Ltd. A novel lactic acid bacteria and its applications
KR102101692B1 (ko) * 2018-03-05 2020-04-20 주식회사 엠디헬스케어 락토바실러스 속 세균 유래 나노소포 및 이의 용도
ES2954685T3 (es) * 2018-06-01 2023-11-23 Nzym Deutschland Gmbh Microvesículas derivadas de productos de origen vegetal fermentados, método para su preparación y utilización
TWI718402B (zh) * 2018-08-16 2021-02-11 葡萄王生技股份有限公司 副乾酪乳酸桿菌gks6之活性物質、含其之組合物及其促進長壽之用途
US12036254B2 (en) * 2018-10-26 2024-07-16 Lac2biome S.r.l. Bacterial strains of the Lactobacillus paracasei species for use, oral or topical, in the treatment of disorders of the female urogenital tract
US10987386B2 (en) * 2018-12-31 2021-04-27 Md Healthcare Inc. Method for treating inflammation or cancer using extracellular vesicles derived from Lactobacillus paracasei
KR102098067B1 (ko) 2018-12-31 2020-04-07 주식회사 엠디헬스케어 락토바실러스 파라카제이 유래 소포 및 이의 용도
CN114728062A (zh) * 2019-09-23 2022-07-08 密执安大学评议会 用于提高免疫疗法和疫苗功效的组合物和方法
US20230000929A1 (en) * 2019-11-26 2023-01-05 Board Of Regents, The University Of Texas System Bdellovibrio treatment for amyotrophic lateral sclerosis
AU2021291569A1 (en) * 2020-06-16 2022-10-20 Md Healthcare Inc. Composition for prevention or treatment of neurological or mental disorders comprising extracellular vesicles derived from lactobacillus paracasei
KR102257130B1 (ko) * 2020-06-16 2021-05-28 주식회사 엠디헬스케어 락토바실러스 파라카세이 유래 소포를 포함하는 신경질환 또는 정신질환 예방 또는 치료용 조성물

Also Published As

Publication number Publication date
CN114144239B (zh) 2024-03-19
US20210386800A1 (en) 2021-12-16
JP2023171724A (ja) 2023-12-05
AU2021291569A1 (en) 2022-10-20
EP3957316B1 (en) 2024-02-07
EP3957316A4 (en) 2022-11-02
US20230256040A1 (en) 2023-08-17
JP7385301B2 (ja) 2023-11-22
US11672838B2 (en) 2023-06-13
EP3957316C0 (en) 2024-02-07
CA3181432A1 (en) 2021-12-23
JP2022542734A (ja) 2022-10-07
CN114144239A (zh) 2022-03-04
EP3957316A1 (en) 2022-02-23
MX2022015535A (es) 2023-01-30

Similar Documents

Publication Publication Date Title
BR112022025626A2 (pt) Uso de vesículas derivadas de lactobacillus paracasei
JOP20200156A1 (ar) إيسكيتامين لعلاج الاكتئاب
BR112013031117A8 (pt) Scilo-inositol para o tratamento de transtornos comportamentais e psiquiátricos.
Carano et al. Glycopyrrolate and theophylline for the treatment of severe pallid breath-holding spells
BR112021017314A2 (pt) Uso de extrato de elaeocarpus sylvestris
MY197917A (en) Use of lactic acid bacteria to treat or prevent gestational diabetes mellitus
US8440243B2 (en) OM vitamin formula
Gosek¹ et al. Effectiveness of ketamine in depressed patients resistant to ECT or rTMS therapy
MX2021015377A (es) Acidos grasos omega 3 y colina como neuroprotectores en pacientes sin demencia.
US20140348949A1 (en) Om vitamin formula
CN105456265B (zh) 一种盐酸非索非那定在制备治疗精神分裂症药物中的应用
Poster Safety and Tolerability of ZYN002 (Synthetic Cannabidiol) Transdermal Permeation-Enhanced Gel in Healthy Subjects and Epilepsy Patients: Three Phase 1, Randomized, Double-Blind, Placebo-Controlled Studies
CN105998552A (zh) 一种舒缓肌肉不适及皮肤痕痒的组合物
EP4327815A3 (en) Probiotics for regulating blood glucose
Zadeh et al. Assessment of the impact of massaging with aromatic oil on relieving itchy skin in the patients undergoing dialysis.
BR112015020566A2 (pt) moduladres de ror gama
EP3071197B1 (en) Food for special medical purposes or food supplement formulation for treating hearing disturbances
TWI544928B (zh) 麥角固醇於製造藥劑之用途
CN110575558A (zh) 安神助眠的空气清新剂
MX2019013717A (es) Plasma de origen animal o fracciones del mismo para usarse en el tratamiento contra trastornos del deterioro cognitivo en humanos y animales de compañia.
CA3076180C (en) Benzoic acid or a salt and derivative thereof for use in preventing or treating depression
Erdos et al. Trifluoperazine in refractory schizophrenic patients
Roodneshin et al. Incidence of Oculocardiac Reflex in Pediatric Population Undergoing Corrective Strabismus Surgery: Comparison between Sevoflurane and Total Intravenous Anesthesia
Darmaputri et al. Evidence based case report: Pyridoxine supplementation in children with pervasive developmental disorders
Shi et al. Trichloropropane and dichlorohydrin associated with painful peripheral neurotoxicity